UK authority in new home by year end:
This article was originally published in Clinica
Moves are being taken to ensure that the staff of the medical devices and pharmaceutical sections of the UK's Medicines and Healthcare products Regulatory Agency, the MHRA, are on the same or adjacent sites by the end of the year. That was what Professor Kent Woods told the industry when he spoke at the 12th Annual Conference of the Association of British Health-Care Industries on June 24. He added that the regulatory agency will also "clearly need to remain financially solvent". The former Medical Devices Agency was due to move out of its Elephant & Castle, south London premises anyway, due to the lease expiring this year, but the merger between the device and pharmaceutical regulatory authorities and synergies between the two sectors has underlined the wisdom of keeping the two units together.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.